Delving into the Latest Updates on XJN010 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

XJN010

Target-

Action-

Mechanism-

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic Disease

Active Indication

Parkinson Disease

Inactive Indication-

Originator Organization

Guangzhou Novaken Pharmaceutical Co., Ltd.

Active Organization

Jewim Pharmaceutical (Shandong) Co., Ltd

Guangzhou Novaken Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

主要目的：（1）在中国健康受试者中评估XJN010鼻喷雾剂相对于卡左双多巴缓释片的生物利用度；（2）在中国健康受试者中评估XJN010鼻喷雾剂单次给药后的药代动力学（PK）特征。次要目的：在中国健康受试者中评估XJN010鼻喷雾剂单次给药后的安全性。

[Translation]

Primary objectives: (1) To evaluate the bioavailability of XJN010 nasal spray relative to carbocycline sustained-release tablets in healthy Chinese subjects; (2) To evaluate the pharmacokinetic (PK) characteristics of XJN010 nasal spray after a single dose in healthy Chinese subjects. Secondary objectives: To evaluate the safety of XJN010 nasal spray after a single dose in healthy Chinese subjects.

Start Date24 Mar 2025

Sponsor / Collaborator

Jewim Pharmaceutical (Shandong) Co., Ltd

[+1]

100 Clinical Results associated with XJN010

Login to view more data

100 Translational Medicine associated with XJN010

Login to view more data

100 Patents (Medical) associated with XJN010

Login to view more data

100 Deals associated with XJN010

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Parkinson Disease	Phase 2	China	Jewim Pharmaceutical (Shandong) Co., Ltd	29 Aug 2025
Parkinson Disease	Phase 2	China	Guangzhou Novaken Pharmaceutical Co., Ltd.	29 Aug 2025